



**LUPIN**

December 26, 2016

✓ **BSE Limited,**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Dear Sir/Madam,**

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a press release as regards receipt of tentative approval by the Company from the USFDA for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg to market a generic version of Daiichi Sankyo Inc's Benicar® Tablets, 5 mg, 20 mg and 40 mg.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

*A. P. Gadgil*

For **R. V. SATAM**  
**COMPANY SECRETARY**

**Encl.: a.a.**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)



**LUPIN**

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

## **Lupin Receives Tentative Approval for Generic Benicar® Tablets**

*Lupin's 150<sup>th</sup> ANDA approval*

**Mumbai, Baltimore, December 26, 2016:** Pharma Major Lupin Limited (Lupin) announced today that it has received tentative approval for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (FDA) to market a generic version of Daiichi Sankyo Inc's Benicar® Tablets, 5 mg, 20 mg and 40 mg.

Lupin's Olmesartan Medoximil Tablets 5mg, 20 mg and 40 mg are the AB rated generic equivalents of Daiichi Sankyo Inc's Benicar® Tablets, 5 mg, 20 mg and 40 mg. Olmesartan Medoximil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents to lower blood pressure.

Benicar® Tablets had US sales of USD 1.06 billion (IMS MAT September 2016).

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 6<sup>th</sup> and the 8<sup>th</sup> largest generics pharmaceutical company by market capitalization and sales globally (September 30<sup>th</sup>, 2016, Bloomberg). The Company is the 5<sup>th</sup> largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3<sup>rd</sup> largest Indian pharmaceutical company by revenues; the 6<sup>th</sup> largest generic pharmaceutical player in Japan and the 4<sup>th</sup> largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31<sup>st</sup> March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### **For further information or queries please contact –**

Shamsher Gorawara  
Head – Corporate Communications  
Lupin Limited  
Ph: +91 98 20 338 555  
Email: [shamshergorawara@lupin.com](mailto:shamshergorawara@lupin.com)

or

## Press Release



**LUPIN**

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Arvind Bothra  
Head – Investor Relations and M&A  
Ph: +91-70 45 656 895  
Email: arvindbothra@lupin.com

*\*Safe Harbor Statement*

*Benicar® is the registered trademark of Sankyo Pharma, Inc.*